AbbVie Dives into STING and Boehringer Ingelheim Snaps Up Swiss-based AMAL

艾伯维(AbbVie) Dives 进军 STING 和勃林格殷格翰(Boehringer Ingelheim)抢购瑞士 AMAL

2019-07-15 23:37:37 BioSpace

本文共1610个字,阅读需5分钟

AbbVie and Boehringer Ingelheim both flexed their M&A muscles this morning with deals that will enhance their oncology pipelines. Illinois-based AbbVie dove into the STING (STimulator of INterferon Genes) pathway with the acquisition of Seattle-based Mavupharma. The STING pathway has become an important area of study for numerous companies. The STING pathway plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens, including the development of cancerous tumors. Enhancing the STING pathway has shown promise in multiple tumor models, AbbVie said in its announcement this morning. STING pathway stimulation has the potential to increase the susceptibility of tumors and broaden treatment options for patients, the company added. Mavupharma's lead clinical candidate is MAVU-104, a first-in-class, orally active, small molecule inhibitor of ENPP1, an enzyme involved in the regulation of the STING pathway. Inhibiting ENPP1 activity with MAVU-104 allows for highly controlled enhancement of STING signaling in tumors without the need for injections. When STING is activated to ward off an invading pathogen, the body begins to produce inflammatory proteins called cytokines and interferons. Those inflammatory proteins then kick the innate immune system into gear, which then produces T cells to destroy the pathogens. Steve Davidson, AbbVie’s head of oncology discovery, said Mavupharma's platform has the potential to further AbbVie’s immuno-oncology portfolio and assist in the development of transformative medicines for patients. Davidson said AbbVie’s oncology vision is to “advance breakthrough areas of science” that will lead to a strong pipeline of innovative cancer therapies. Financial terms of the acquisition were not disclosed. There was also no word on whether or not the employees at Mavupharma will be absorbed into AbbVie or if cuts will be made to avoid redundancies. Other companies in the STING field include Boston-based IFM Therapeutics, Nimbus Therapeutics, California-based Aduro Biotech, Pharma giants Merck and Eli Lilly. Also striking a deal this morning to advance its oncology pipeline is Germany-based Boehringer Ingelheim. The company acquired Switzerland-based AMAL Therapeutics SA. The privately-held company is focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. ATP128 is a therapeutic chimeric recombinant protein vaccine. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform, the company said this morning. KISIMA enables the assembly of three functional components into one patented fusion protein used as a vaccine. Under terms of the deal, Boehringer Ingelheim made an undisclosed upfront payment to AMAL. The total deal could amount to €325 million, which includes clinical, development and regulatory milestones, as well as an additional €100 million if certain commercial milestones are hit. Michel Pairet, a member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit, said acquiring AMAL is part of the company’s strategy to enhance its position as an innovator of novel cancer therapies, including immuno-oncology treatments.  “We want to pioneer new paradigms of biology-based care for cancer patients, and the technologies and expertise developed at AMAL are critical to our efforts,” Pairet said in a brief statement. The AMAL deal will boost previous acquisitions made by Boehringer Ingelheim, including the 2018 acquisition of Vira Therapeutics and the in-licensing of OSE Immunotherapeutics’ SIRP-alpha targeting antibody.
艾伯维(AbbVie)和勃林格殷格翰(Boehringer Ingelheim)今天上午都宣布了他们的并购计划,这将加强他们的肿瘤治疗管道。 伊利诺伊州的艾伯维(AbbVie)鸽子进入 STING ( INterferon 基因的 STiminator )途径与收购总部位于西雅图的 Mavpharma 。STING 途径已成为众多企业研究的重要领域。STION 途径在先天性免疫系统中发挥重要作用,免疫系统是机体对抗各种病原体的第一道防线,包括肿瘤的发展。增强 STING 通路在多种肿瘤模型中显示出了希望,艾伯维(AbbVie)在今天上午的声明中说。公司补充称, STING 通路刺激有可能增加肿瘤的易感性,拓宽患者的治疗选择。 Mavpharma 的主要临床候选药物是 MAVU-104,是 ENPP1的一级、口服活性小分子抑制剂,是一种参与调节 STING 途径的酶。用 MAVU-104抑制 ENPP1活性,可以在不需要注射的情况下高度控制肿瘤 STING 信号的增强。当 STING 被激活以阻止入侵的病原体时,身体开始产生一种叫做细胞因子和干扰素的炎症蛋白。然后这些炎症蛋白将天生的免疫系统注入齿轮中,然后产生 T 细胞来破坏病原体。 AbbVie 肿瘤学发现负责人 Steve Davidson 表示, Mavpharma 的平台有潜力进一步促进艾伯维(AbbVie)的免疫肿瘤组合,并协助为患者开发转化药物。Davidson 表示,艾伯维(AbbVie)的肿瘤学愿景是“推进科学的突破性领域”,这将导致创新癌症治疗的强大渠道。 本次收购的财务条款未披露。此外,也没有任何消息表明,是否 Mavpharma 的员工将被吸收到艾伯维(AbbVie),或是否将削减,以避免裁员。STING 领域的其他公司包括总部位于波士顿的 IFM Therapeutics 、 Nimbus Therapeutics 、总部位于加州的 Aduro Biotech 、制药巨头默克(Merck)和礼来(Eli Lilly)公司。 今天上午达成的推进肿瘤治疗的协议也是总部位于德国的勃林格殷格翰(Boehringer Ingelheim)。该公司收购了总部位于瑞士的 AMAL Therapeutics SA 。民营控股公司专注于肿瘤免疫治疗,推进从其技术平台 KISIMA 衍生的一流治疗肿瘤疫苗的研发。AMAL 的领先疫苗 ATP128目前用于第四期结直肠癌,预计将于本月晚些时候开始首次人体试验。ATP128是一种治疗性嵌合重组蛋白疫苗。该公司今天上午表示,勃林格殷格翰(Boehringer Ingelheim)公司计划将其癌症免疫产品组合中的资产与 AMAL 专有的 KISIMA 免疫平台结合起来,开发新的治疗方法。KISIMA 能够将三种功能组件组装成一种专利的融合蛋白作为疫苗。 根据交易条款,勃林格殷格翰(Boehringer Ingelheim)向 AMAL 支付了一笔未披露的预付款。这笔交易总额可能达到3.25亿欧元,其中包括临床、开发和监管里程碑,如果某些商业里程碑达到,还将增加1亿欧元。 勃林格殷格翰(Boehringer Ingelheim)负责该公司创新部门的董事总经理 Michel Paret 表示,收购 AMAL 是该公司战略的一部分,以增强其作为包括免疫肿瘤治疗在内的新型癌症治疗创新药物的地位。 “我们希望开创基于生物学的癌症患者护理新模式, AMAL 开发的技术和专业知识对我们的努力至关重要,” Paret 在一份简短声明中表示。 AMAL 的交易将促进勃林格殷格翰(Boehringer Ingelheim)之前的收购,包括2018年收购 Vira Therapeutics ,以及获得 OSE Immunotherapeutics 的 SIRP-alpha 靶向抗体的许可。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文